Mycoplasma pneumonia

Mycoplasma pneumonia is a bacterial respiratory infection caused by *Mycoplasma pneumoniae* and described in the sources as a common cause of pneumonia and a major agent of community-acquired pneumonia ^[2][1]. The organism is also linked in the literature to acute inflammation of the upper and lower respiratory tract and to extrapulmonary syndromes ^[1]. Source-backed detail on formal case definitions or standardized classification is not yet available ^[1][2].

The source abstracts describe a syndrome of primary atypical pneumonia with cough, fever, chills, headache, and malaise, together with segmental or subsegmental pulmonary infiltrates and a white blood cell count that is normal or only slightly elevated ^[2]. A second presentation is noted in which lethargy, dyspnea, and 1 to 4 weeks of shortness of breath may occur without cough or fever, with diffuse reticulonodular or interstitial infiltrates ^[2]. The illness is usually benign and self-limiting in previously healthy hosts, but refractory pneumonia can be life-threatening ^[2][1]. Serious disease is reported in infants, older adults, and patients with other underlying diseases or immunodeficiency states ^[1][2].

The available sources characterize *M. pneumoniae* as a common cause of pneumonia and a major agent of community-acquired disease, but they do not provide population incidence or seasonal distribution ^[2][1]. Macrolide-resistant *M. pneumoniae* has emerged in Asia, indicating documented regional antimicrobial-resistance concern in the literature ^[3]. The 2014 review notes that epidemiologic knowledge of atypical pathogens remains limited, and that wider molecular testing may improve understanding of their epidemiology and presentation ^[3]. Source-backed detail on outbreak setting, reservoir, or surveillance burden is not yet available ^[1][3].

The supplied sources do not provide a direct description of transmission route or exposure mechanism for *Mycoplasma pneumoniae* ^[1][2][3]. They do identify the organism as a respiratory pathogen associated with community-acquired pneumonia, which supports a respiratory disease context but not a specific transmission statement ^[1][2]. Source-backed detail on persistence, contagion period, or environmental transmission is not yet available ^[1][3].

The sources specifically identify infants and the elderly as groups in whom refractory pneumonia may be life-threatening ^[1]. They also report that disease can be very serious in patients with other conditions including sickle cell anemia, sarcoidosis, systemic lupus erythematosus, Hodgkin's disease, and various immunodeficiency states ^[2]. Source-backed detail on other high-risk groups is not yet available ^[1][2].

The source material emphasizes prevention through vaccine development, stating that an effective vaccine is urgently needed to prevent *M. pneumoniae* infections in children ^[1]. It also notes that several vaccine types have been reported, including whole-cell, subunit, and DNA vaccines, though no schedule or implementation details are provided ^[1]. No additional source-backed public-health prevention measures are described in the supplied snippets ^[1][3].

In surveillance terms, this disease is best read as a community-acquired atypical pneumonia syndrome with a broad clinical spectrum, including cases with extrapulmonary features and refractory pneumonia ^[1][2]. The literature also highlights diagnostic and epidemiologic uncertainty, including carriage-versus-infection challenges and the expanding use of molecular testing in respiratory specimens ^[3]. Source-backed detail on routine notification criteria, thresholds, or standardized weekly surveillance interpretation is not yet available ^[1][3].

1. 1 Jiang Z et al. Mycoplasma pneumoniae Infections: Pathogenesis and Vaccine Development. Pathogens. 2021 Jan 25. PMID: 33503845. doi: 10.3390/pathogens10020119. PubMed: https://pubmed.ncbi.nlm.nih.gov/33503845/
2. 2 Jensen PS et al. Mycoplasma pneumonia. CRC Crit Rev Diagn Imaging. 1980. PMID: 6767579. PubMed: https://pubmed.ncbi.nlm.nih.gov/6767579/
3. 3 Basarab M et al. Atypical pneumonia. Curr Opin Pulm Med. 2014 May. PMID: 24626238. doi: 10.1097/MCP.0000000000000048. PubMed: https://pubmed.ncbi.nlm.nih.gov/24626238/
4. 4 Mycoplasma pneumonia. Radiopaedia.org. 2013. doi: 10.53347/rid-25082. DOI: https://doi.org/10.53347/rid-25082
5. 5 Mycoplasma Pneumonia. Radiology of Infectious and Inflammatory Diseases - Volume 3. 2023. doi: 10.1007/978-981-99-4614-3_9. DOI: https://doi.org/10.1007/978-981-99-4614-3_9
6. 6 Mycoplasma Pneumonia. New England Journal of Medicine. 1971. doi: 10.1056/nejm197110142851618. DOI: https://doi.org/10.1056/nejm197110142851618

ICD-10

ICD-11

Total cases

125K

Peak month

2024-11

Coverage

1 reporting countries · 2012-09-15 → 2026-06-20